imatinibimatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. imatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. indapamidetadalafil increases effects of indapamide by pharmacodynamic synergism.
elagolix decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust tadalafil dose for PAH; if on Stribild, start tadalafil 20 mg/day; avoid tadalafil when starting Stribild; for ED, a single dose of tadalafil not exceeding 10 mg in 72 hr. enalapriltadalafil increases effects of enalapril by pharmacodynamic synergism. tadalafil increases effects of enalapril by pharmacodynamic synergism. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations.
Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents. eplerenonetadalafil increases effects of eplerenone by pharmacodynamic synergism. tadalafil increases effects of eplerenone by pharmacodynamic synergism. eprosartantadalafil increases effects of eprosartan by pharmacodynamic synergism. tadalafil increases effects of eprosartan by pharmacodynamic synergism. tadalafil increases effects of indapamide by pharmacodynamic synergism. irbesartantadalafil cialis drug cost increases effects of irbesartan by pharmacodynamic synergism. tadalafil increases effects of irbesartan by pharmacodynamic synergism. isoniazidisoniazid will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. isoniazid will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. isradipinetadalafil increases effects of isradipine by pharmacodynamic synergism.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Original | 20mg | 14 + 2 Pills | 95.75€ 91.19€ | |
| Cialis Professional | 40mg | 120 + 4 Pills | 436.68€ 415.89€ | |
| Cialis Generic | 2.5mg | 120 + 6 Pills | 128.93€ 122.79€ | |
| Cialis Black | 80mg | 180 + 10 Pills | 356.64€ 339.66€ | |
| Cialis Generic | 5mg | 10 Pills | 29.39€ 27.99€ | |
| Cialis Soft Tabs | 20mg | 270 + 10 Pills | 471.40€ 448.95€ | |
| Cialis Soft Tabs | 20mg | 90 + 6 Pills | 216.71€ 206.39€ | |
| Cialis Original | 20mg | 22 + 2 Pills | 129.20€ 123.05€ | |
| Cialis Generic | 20mg | 360 + 10 Pills | 427.34€ 406.99€ | |
| Cialis Generic | 60mg | 120 + 8 Pills | 240.18€ 228.74€ | |
| Cialis Super Active | 20mg | 120 + 16 Pills | 382.15€ 363.95€ | |
| Cialis Generic | 2.5mg | 20 Pills | 40.73€ 38.79€ | |
| Cialis Generic | 5mg | 360 + 10 Pills | 268.08€ 255.31€ |
tadalafil increases effects of isradipine by pharmacodynamic synergism. istradefyllineistradefylline will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day.
dronedaronedronedarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dronedarone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. duvelisibduvelisib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.
duvelisib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenzefavirenz will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. elagolixelagolix decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider increasing CYP3A substrate dose if needed. Consider dose reduction of sensitive CYP3A4 substrates. istradefylline will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. labetaloltadalafil increases effects of labetalol by pharmacodynamic synergism. tadalafil increases effects of labetalol by pharmacodynamic synergism. lapatiniblapatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lapatinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. letermovirletermovir increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
letermovir increases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lisinopriltadalafil increases effects of lisinopril by pharmacodynamic synergism. tadalafil increases effects of lisinopril by pharmacodynamic synergism. losartantadalafil increases effects of losartan by pharmacodynamic synergism. tadalafil increases effects of losartan by pharmacodynamic synergism.
fedratinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. felodipinetadalafil increases effects of felodipine by pharmacodynamic synergism. tadalafil increases effects of felodipine by pharmacodynamic synergism. fluconazolefluconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluconazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
fluvoxaminefluvoxamine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fluvoxamine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosaprepitantfosaprepitant will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosaprepitant will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosinopriltadalafil increases effects of fosinopril by pharmacodynamic synergism. lumefantrinelumefantrine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
| Contraindication | Description | Alternative Actions |
|---|---|---|
| Nitrate use | Dangerous interaction causing hypotension | Consult doctor for alternatives |
| Heart conditions | Risk of cardiovascular events | Medical evaluation before use |
| Liver or Kidney impairment | Altered drug metabolism | Dose adjustment or avoid medication |
| Allergies to Tadalafil | Potential allergic reactions | Discontinue use and seek medical advice |
lumefantrine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. marijuanamarijuana will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. marijuana will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mavorixaformavorixafor will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor for adverse effects of sensitive CYP3A4 substrates if coadministered with mavorixafor (a weak CYP3A4 inhibitor).
mavorixafor will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. metolazonetadalafil increases effects of metolazone by pharmacodynamic synergism. tadalafil increases effects of metolazone by pharmacodynamic synergism.
| Patient Group | Recommended Dose | Frequency | Special Instructions |
|---|---|---|---|
| Adults with ED | 5 mg | Once daily as needed | Take 30 mins before activity |
| Elderly Patients | 5 mg | As prescribed | Be cautious of interactions |
| Patients with Liver | Adjusted dose as per doctor | Once daily | Consult physician |
metoprololtadalafil increases effects of metoprolol by pharmacodynamic synergism.
tadalafil increases effects of guanfacine by pharmacodynamic synergism. hydralazinetadalafil increases effects of hydralazine by pharmacodynamic synergism. tadalafil increases effects of hydralazine by pharmacodynamic synergism. hydrochlorothiazidetadalafil increases effects of hydrochlorothiazide by pharmacodynamic synergism. tadalafil increases effects of hydrochlorothiazide by pharmacodynamic synergism. tadalafil increases effects of metoprolol by pharmacodynamic synergism. metronidazolemetronidazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. metronidazole will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mifepristonemifepristone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mifepristone will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
tadalafil increases effects of fosinopril by pharmacodynamic synergism. fosphenytoinfosphenytoin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosphenytoin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. furosemidetadalafil increases effects of furosemide by pharmacodynamic synergism. tadalafil increases effects of furosemide by pharmacodynamic synergism.
grapefruitgrapefruit will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. grapefruit will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. griseofulvingriseofulvin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. griseofulvin will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. guanfacinetadalafil increases effects of guanfacine by pharmacodynamic synergism. minoxidiltadalafil increases effects of minoxidil by pharmacodynamic synergism. tadalafil increases effects of minoxidil by pharmacodynamic synergism. mitotanemitotane decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
eslicarbazepine acetate will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. esmololtadalafil increases effects of esmolol by pharmacodynamic synergism. tadalafil increases effects of esmolol by pharmacodynamic synergism. ethacrynic acidtadalafil increases effects of ethacrynic acid by pharmacodynamic synergism. tadalafil increases effects of ethacrynic acid by pharmacodynamic synergism.
Combination may increase risk of orthostatic hypotension, tachycardia, dizziness and headache. etravirineetravirine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. etravirine will decrease the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fedratinibfedratinib will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dose of drugs that are CYP3A4 substrates as necessary. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.
mitotane decreases levels of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.